Dolutegravir, a second-generation HIV Integrase Strand Transfer Inhibitor (INSTI), is the most current antiretroviral ratified for treatment of HIV-1 infection. This approval is based on the superiority of Dolutegravir in clinical trials over the well-known antiretroviral marketed drugs like Efavirenz, Raltegravir, and Darunavir. Largely, Dolutegravir has established excellent tolerability, limited drug interactions, insignificant drug resistance and once-daily dosing for treatment-naive patients. (R)-3-amino butanol is a key unit for the synthesis of Dolutegravir and rarer methods of synthesis are mentioned in the literature.
Select your language of interest to view the total content in your interested language